Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide

International Journal of Cancer

Volumn 76, Issue 6, 1998, Pages 817-823

  Reddish, Mark A ^a   MacLean, Grant D ^b,c   Rao Koganty, R ^b   Kan Mitchell, June ^d   Jones, Vicky ^d   Mitchell, Malcolm S ^d   Longenecker, B Michael ^b  

^a ID Vaccine   (United States)

^b Biomira Inc   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADENOCARCINOMA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; TARGET CELL;

BREAST NEOPLASMS; CA-15-3 ANTIGEN; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; NEOPLASM METASTASIS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032503501     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980610)76:6<817::AID-IJC9>3.0.CO;2-0     Document Type: Article

References (38)

1. ACRES, R.B., HAREUVENI, M., BALLOUL, J.-M. and KIENY, M.-P., Vaccinia virus MUC1 immunization of mice: Immune response and protection against the growth of murine tumors bearing the MUC1 antigen. J. lmmunother., 14, 136-143 (1993).
2. AGRAWAL, B., KRANTZ, M.J., REDDISH, M.A. and LONGENECKER, B.M., Cancer associated MUC-1 mucin inhibits human T-cell proliferation which is reversible by IL-2. Nature (Med.), 4, 43-49 (1998).
3. AGRAWAL, B., REDDISH, M.A. and LONGENECKER, B.M., In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J. Immunol., 157, 2089-2095 (1996).
4. APOSTOLOPOULOS, V., KARANIKAS, V., HAURUM, J.S. and MCKENZIE, I.F.C., Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol., 159, 5211-5218 (1997).
5. APOSTOLOPOULOS, V., LOVELAND, B.E., PIETERSZ, G.A. and MC-KENZIE, I.F.C., CTL in mice immunized with human mucin 1 are MHC-restricted. J. Immunol., 155, 5089-5094 (1995).
6. APOSTOLOPOULOS, V., XING, P.-X. and MCKENZIE, I.F.C., Murine immune responses to cells transfected with human MUC1: immunization with cellular and synthetic antigens. Cancer Res., 54, 5186-5193 (1994).
7. BARND, D.L., LAN, M.S., METZGAR, R.S. and FINN, O.J., Specific major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. nat. Acad. Sci. (Wash.), 86, 7159-7163 (1989).
8. BERRY, N., JONES, D.B., SMALLWOOD, J., TAYLOR, I., KIRKHAM, N. and TAYLOR-PAPADIMITRIOU, J., The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer. Brit. J. Cancer, 51, 179-186 (1985).
9. BOHM, C., MULDER, M., ZENNADI, R., NOTTER, M., SCHMITT-GRAFF, A., FINN, O., TAYLOR-PAPADIMITRIOU, J., STEIN, H., CLAUSEN, H., RIECKEN, E. and HANSKI, C., Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation. Scand. J. Immunol., 46, 27-34 (1997).
10. BORGES, E., WIESMULLER, K.-H., JUNG, G. and WALDEN, P., Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid. J. immunol. Methods, 173, 253-263 (1994).
11. BURCHELL, J., GENDLER, S., TAYLOR-PAPADIMITRIOU, J., GIRLING, A., LEWIS, A., MILLIS, R. and LAMPORT, D., Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res., 47, 5476-5482 (1987).
12. + T cell responses: the alternative approaches. Ann. Rev. Immunol., 15, 297-322 (1997).
13. CORMIER, J.N., SALGALLER, M.L., PREVETTE, T., BARRACCHINI, K.C., RIVOLTINI, L., RESTIFO, N.P., ROSENBERG, S.A. and MARINCOLA, F.M., Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/melan A. Cancer J. Sci. Amer. 3, 37-44 (1997).
14. CORREALE, P., WALMSLEY, K., NIERODA, C., ZAREMBA, S., ZHU, M., SCHLOM, J. and TSANG, K.Y., In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. nat. Cancer Inst., 89, 293-300 (1997).
15. DEFOORT, J.-P., NARDELLI, B., HUANG, W., HO, D.D. and TAM, J.P., Macromolecular assemblage in the design of a synthetic AIDS vaccine. Proc. nat. Acad. Sci. (Wash.), 89, 3879-3883 (1992).
16. DING, L., LALANI, E.-N., REDDISH, M., KOGANTY, R., WONG, T., SAMUEL, J., YACYSHYN, M.B., TAYLOR-PAPADIMITRIOU, J. and LONGENECKER, B.M., Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother., 36, 9-17 (1993).
17. DISIS, M.L., SMITH, J.W., MURPHY, A.E., CHEN, W. and CHEEVER, M.A., In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res., 54, 1071-1076 (1994).
18. DOMENECH, N., HENDERSON, R.A. and FINN, D.J., Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol., 155, 4766-1774 (1995).
19. FORTIS, C. and CLEMENTI, E., Reversible lymphocyte anergy during IL-2 therapy. Immunol. Today, 18, 254 (1997).
20. GENDLER, S., TAYLOR-PAPADIMITRIOU, J., DUHIG, T., ROTHBARD, J. and BURCHELL, J.A., A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J. biol. Chem., 263, 12820-12823 (1988).
21. GILEWSKI, T., ADLURI, R., ZHANG, S., HOUGHTON, A., NORTON, L. and LIVINGSTON, P., Preliminary results: vaccination of breast cancer patients (PTS) lacking identifiable disease (NED) with MUC-1-keyhole limpet hemocyanin (KLH) conjugate and QS21. ASCO Proc., 15, 555 (1990).
22. HOUBIERS, J.G., NIJMAN, H.W., VAN DER BURG, S.H., DRIJFHOUT, J.W., KENEMANS, P., VAN DE VELDE, C., BRAND, A., MOMBURG, F., KAST, W.M. and MELIEF, C.J.M., In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Europ. J. Immunol., 23, 2072-2077 (1993).
23. JEROME, K.R., BARND, D.L., BENDT, K.M., BOYER, C.M., TAYLOR-PAPADIMITRIOU, J., MC-KENZIE, I.F.C., BAST, JR., R.C. and FINN, O.J., Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res., 51, 2908-2916 (1991).
24. JEROME, K.R., DOMENECH, N. and FINN, O.J., Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B complementary DNA. J. Immunol., 151, 1654-1662 (1993).
25. KANG, X., KAWAKAMI, Y., EL-GAMIL, M., WANG, R., SAKAGUCHI, K., YANNELLI, J.R., APPELLA, E., ROSENBERG, S.A. and ROBBINS, P.F., Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J. Immunol., 155, 1343-1348 (1995).
26. KANTOR, J., IRVINE, K., ABRAMS, S., KAUFMAN, H., DI PIETRO, J. and SCHLOM, J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. nat. Cancer Inst., 84, 1084-1091 (1992).
27. KAWAKAMI, Y., ELIYAHU, S., JENNINGS, C., SAKAGUCHI, K., KANG, X., SOUTHWOOD, S., ROBBINS, P.F., SETTE, A., APPELLA, E. and ROSENBERG, S.A., Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol., 154, 3961-3968 (1995).
28. KAWAKAMI, Y., ELIYAHU, S., SAKAGUCHI, K., ROBBINS, P.F., RIVOLTINI, L., YANNELLI, J.R., APPELLA, E. and ROSENBERG, S.A., Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. exp. Med., 180, 347-352 (1994).
29. MACLEAN, G.D., MILES, D.W., RUBENS, R.D., REDDISH, M.A. and LONGENECKER, B.M., Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J. Immunother., 19, 309-316 (1996).
30. MACLEAN, G.D., REDDISH, M.A. and LONGENECKER, B.M., Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. J. Immunother., 20, 70-78 (1997).
31. RIVOLTINI, L., KAWAKAMI, Y., SAKAGUCHI, K., SOUTHWOOD, S., SETTE, A., ROBBINS, P.F., MARINCOLA, F.M., SALGALLER, M.L., YANNELLI, J.R., APPELLA, E. and ROSENBERG, S.A., Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol., 154, 2257-2265 (1995).
32. SAMUEL, J., BUDZYNSKI, W.A., REDDISH, M.A., DING, L., ZIMMERMANN, G.L., KRANTZ, M.J., KOGANTY, R.R. and LONGENECKER, B.M., Immunogenicity and antitumor activity of a liposomal MUC1 peptide based vaccine. Int. J. Cancer 75, 295-302 (1998).
33. + CTL in vivo with peptide vaccine constructs. J. Immunol., 152, 549-556 (1994).
34. TINDLE, R.W., CROFT, S., HERD, K., MALCOLM, K., GECZY, A.F. STEWART, T. and FERNANDO, G.J.P., A vaccine conjugate of "ISCAR" immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clin. exp. Immunol., 101, 265-271 (1995).
35. TSANG, K.Y., NIERODA, C.A., DE FILIPPI, R., CHUNG, Y.K., YAMAUE, H., GREINER, J.W. and SCHLOM, J., Induction of human cytotoxic T-cell lines directed against point-mutated p21 ras-derived synthetic peptides. Vaccine Res., 3, 183-193 (1994).
36. TSANG, K.Y., ZAREMBA, S., NIERODA, C.A., ZHU, M.Z., HAMILTON, J.M. and SCHLOM, J., Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patents immunized with recombinant vaccinia-CEA vaccine. J. nat. Cancer Inst., 87, 982-990 (1995).
37. ZHANG, S., GRAEBER, L.A., HELLING, F., RAGUPATHI, G., ADLURI, S., LLOYD, K.O. and LIVINGSTON, P.O., Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res., 56, 3315-3319 (1996).
38. ZHOU, F. and HUANG, L., Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes. Vaccine, 11, 1139-1144 (1993).